Bile secretion pathway stimulation

Bile secretion pathway stimulation refers to the activation of complex physiological processes that increase the formation and excretion of bile, a digestive fluid synthesized by hepatocytes and modified by cholangiocytes[1][2][3]. This pathway involves numerous molecular players, including transporters such as BSEP, NTCP, MRP2, and OATP, and is regulated by a variety of receptors (e.g., secretin receptor, FXR, TGR5), hormones (secretin, somatostatin, cholecystokinin), and enzymes (cholesterol 7 alpha-hydroxylase)[1][2][3][4][6]. Stimulation typically leads to increased bile flow, bile salt excretion, and alkaline secretions essential for lipid digestion and cholesterol homeostasis. Disruption or alteration of pathway components is linked to several hepatic and biliary disorders. Note: For drug targeting or biomarker identification, focus should shift from the general pathway to specific molecules (e.g., BSEP, FXR, TGR5) that regulate bile secretion[4]. The current entry does not represent a singular, molecular therapeutic target[1][2][3][4][6].

Other names

bile secretion stimulationbiliary secretion pathway activationcholagogue pathway

Direct receptor agonism (e.g., FXR agonists, TGR5 agonists); Channel activation (e.g., secretin receptor → CFTR); Transporter modulation (e.g., BSEP upregulation, NTCP inhibition); Enzyme activation or inhibition (e.g., cholesterol 7-alpha hydroxylase modulation)